Key Highlights
● The company says Pro Music Rights holds about 7.4% of the US market and represents more than 2.5 million works.
● 2024 revenue fell to $128.9 million from $1.05 billion, turning $46.0 million of net income into a $54.4 million loss.
● Music Licensing is moving toward royalty-generating intellectual property, targeting acquisitions valued from $36 million to $250 million, with none verified.
● Total assets of $19.9 million sit against liabilities of $23.7 million, leaving shareholders' equity of negative $3.8 million.
Music Licensing, Inc. (OTC:SONG), quoted over the counter, owns Pro Music Rights, a performing rights organisation in the United States. Such organisations collect fees for public performances of songs and pay songwriters and publishers. The group is described as based in Naples, Florida, with Jake P. Noch named as chief executive.
The company says Pro Music Rights holds about 7.4% of the United States market and represents more than 2.5 million works, and calls itself the fifth-largest performing rights organisation. Those market-share figures come from the company's own communications, not from an independent industry body.
Performing rights organisations matter because venues such as restaurants, nightclubs, radio stations and streaming services need licences to play music publicly. The company issues public performance licences to businesses, and July 2025 coverage described a flat monthly rate of $50 per location with usage-based pricing capped at $0.01.
The latest verified announcements
The newest item is a press release dated December 11, 2025, in which the company and Pro Music Rights announced potential antitrust and defamation actions in response to what they called mischaracterisations by a Congressman and industry lobby groups. Whether any action was filed was not established. Earlier, on August 27, 2025, the company said it had moved up to the OTC Markets Group's OTCID tier, and the company said in July 2025 it had retained a PCAOB-registered audit firm for statements covering the half-year to June 30, 2025.
Another release said that in February 2025 the subsidiary received official Federal Register recognition as a performing rights organisation.
Financial performance
The fiscal 2024 results, published on February 27, 2025 alongside a Form 1-K filing, show a sharp change. Revenue fell to $128.9 million from $1.05 billion in 2023, and net income of $46.0 million became a net loss of $54.4 million. Total assets were $19.9 million against liabilities of $23.7 million, leaving shareholders' equity of negative $3.8 million.
Management attributed the decline to a strategic shift, including reassessment and reduction of certain accounts receivable and changes in the business model. Revenue of that scale for a company with one reported employee is unusual, and the receivables write-down suggests earlier revenue was recognised on amounts that were later reduced.
The company said it is moving from traditional licensing toward acquiring and trading royalty-generating intellectual property, including interests in music catalogues and the Listerine brand, and identified acquisition targets valued from $36 million to $250 million for 2025. No completed acquisitions were verified.
Royalty Acquisitions and Legal Friction Will Test Music Licensing's Pivot
The shares trade at a fraction of a cent, quoted at $0.0002, with a 52-week range from $0.000001 to $4.95. Market capitalisation and share count readings are not meaningful. Negative equity, limited staffing and reliance on unaudited or lightly reviewed semi-annual figures add to the risk.
Legal and regulatory friction in the licensing industry, which the company itself highlighted in December 2025, could also absorb resources. Such disputes can be costly for a company reporting one employee and negative equity.
The next earnings date was listed as September 11, 2026, a date that has already passed, with no corresponding results, which leaves the current financial position unverified.
Next steps to watch are the fiscal 2025 annual filing, an outcome from the audit review, any evidence of royalty acquisitions closing, and the company's disclosure standard on OTC Markets.






Please wait processing your request...